Science Corp. Raises $400M at $3.5B Valuation to Bring Brain Implants to the U.S.

The investment, led by Khosla Ventures and including Tenet Healthcare, the Ackman Oxman Institute, and PLC Neurotech, will help the company expand its first product, PRIMA, a retinal implant for age-related macular degeneration (AMD), into the U.S. market.
The round highlights Science’s appeal to a mix of investors. The Ackman Oxman Institute, a new research center backed by hedge fund billionaire Bill Ackman, is making its first venture bet, suggesting long-term confidence in the field. Tenet Healthcare’s involvement points to potential partnerships with hospitals, while Y Combinator’s participation ties Science to the startup ecosystem’s credibility.
PRIMA’s U.S. launch depends on FDA approval. The device, already approved in Europe and implanted in German patients, uses a chip with 378 electrodes to stimulate remaining retinal cells. Paired with infrared glasses that process visual input, it aims to restore partial vision. Hodak told *Bloomberg* the device could reach U.S. patients as soon as early next year.
The timing is significant. Neuralink, where Hodak worked earlier, has faced delays and safety concerns, creating skepticism around brain-computer interfaces. Science’s focus on vision restoration, however, offers a clearer regulatory path.
Beyond PRIMA, Science is working on Biohybrid, a brain implant combining cultured neurons with silicon chips to treat neurological disorders. The company has hired Yale neurosurgeon Murat Günel to lead clinical trials, which could begin within 16 months. While the specific condition isn’t disclosed, Günel has previously noted potential for Parkinson’s disease and brain injuries.
The $400 million round reflects growing institutional interest in medical-grade implants. However, Science’s path isn’t guaranteed. The U.S. retinal implant market is fragmented, with unclear insurance coverage for out-of-pocket devices. While the Ackman Oxman Institute’s backing suggests strategic interest, scaling European success in the U.S. will require proving both effectiveness and affordability.
For founders and investors, Science’s progress offers insight into hardware commercialization in healthcare. Unlike software startups, medical device companies face long sales cycles, strict regulations, and high manufacturing costs. The $400 million valuation—without an IPO or acquisition—suggests confidence in Science’s position: a product with limited direct competition in its core area, led by a founder with Neuralink experience.
Pricing details: The company hasn’t revealed PRIMA’s cost, but its partnership with Moorfields Private Eye Hospital implies a premium model—one that may limit adoption without insurance support.
Science’s funding isn’t just about raising capital—it signals that brain and vision implants are moving from research to real-world use. For operators and investors, the question shifts from whether the market will grow to which companies will shape it.
Sources: siliconangle.com
“The funding shows strong investor interest in medical implants, though regulatory and competitive challenges remain ahead.”
Read the original reporting
The outlets below did the original reporting.
Related briefs
- K4Connect Raises $8M to Build AI Agents for Senior Living Workflows
- IntelliProve raises €2.7M to turn smartphones into robot health monitors
- Belgian healthtech startup IntelliProve raises €2.7M to bring facial health scans into hum
- Isomorphic Labs Lands $5B in Largest-Ever UK AI Startup Round—What It Means for Drug Disco
- Treat raises €3M to fix private healthcare’s broken economics—by redesigning the incentive
This brief was drafted automatically from the sources above and published under our editorial policy. Spotted an error? Tell us.